Rigel Q2 revenue $36.8M, net loss narrows to $1.0M; GAVRETO launch adds $1.9M

RIGEL PHARMACEUTICALS INC

2024-Q2 EPS reported -$0.53 revenue$66,375,000

Total Q2 revenue $36.8M; TAVALISSE $26.4M (+24% YoY), REZLIDHIA $5.2M (+102% YoY), GAVRETO $1.9M (launched June 27).
Net loss narrowed to $1.0M ($0.06/share) from $6.6M loss in Q2 2023; approaching net income break-even.
Completed NDA transfer of GAVRETO; product commercially available from Rigel beginning June 27.
Phase 1b trial of R289 in LR-MDS enrolling fourth dose level; preliminary data expected by end of 2024.
Cash and investments $49.1M as of June 30, essentially flat from March 31.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.